semaglutide hepatotoxicity case report Resmetirom and in metabolic dysfunction-associated steatohepatitis (MASH): a comparative perspective semaglutide hepatotoxicity case report A – Safety and efficacy of combination

Vial life and dose planning Understanding how many doses your vial contains helps you plan refills and avoid running out mid-protocol

In people with type 2 diabetes: In people with obesity but not diabetes: Individuals with health risks related to excess weight may also benefit from oral semaglutide

Ozempic and Mounjaro are FDA-approved for type 2 diabetes treatment, but may be prescribed off-label for weight loss at a healthcare providers discretion

Plan around your injection day At 50 units (especially at higher mg doses), the day of injection and the following day may bring stronger side effects

Regular endoscopic surveillance should continue on schedule, with earlier evaluation if symptoms change